Key result
Sacubitril/valsartan and ramipril demonstrated similar efficacy in improving left ventricular ejection fraction at 6 months in post-acute coronary syndrome patients (p=0.275).
Why the study?
Ramipril and sacubitril/valsartan are both used in ACS patients with left ventricle systolic dysfunction, but their relative effects on improving LVEF required direct comparison.
Does sacubitril/valsartan improve LVEF compared to ramipril in post-ACS patients with LVEF ≤40%?
RCT (n=80)
Open-label
Computer generated random number table
No
Does sacubitril/valsartan improve LVEF compared to ramipril in post-ACS patients with LVEF ≤40%?
Sacubitril/valsartan and ramipril are equally effective in improving left ventricular ejection fraction at 6 months in patients with post-ACS left ventricular systolic dysfunction.
Ramipril matches sacubitril/valsartan for LVEF recovery post-ACS; confirms similar efficacy while leaving open questions on hard outcomes.
Background: Ramipril and sacubitril/valsartan are used in the management of ACS patients with left ventricle systolic dysfunction. The objective of the study was to compare ramipril and sacubitril/valsartan in improving LVEF in post ACS patients with LVEF <40%. Methods: A randomized, prospective, open label, comparative study was carried out in department of pharmacology and cardiology at Dr. R. P. G. M. C. Kangra at Tanda, Himachal Pradesh. The study was carried for a period of one and a half year. Out of 80 patients, 38 patients were in ramipril group and 42 were in sacubitril/valsartan group. Data was presented as mean±SD, frequency and percentage. Student’s t test and chi square test were used and p value<0.05 was considered significant. Results: In both the groups, a statistically significant improvement was observed in terms of improvement in LVEF at 6th month when compared to baseline, however, at 6th month both the groups were comparable in terms of LVEF improvement with p value of 0.275. Conclusions: The study concluded that both the drugs have same efficacy in improving LVEF in post ACS patients at 6th month.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2023) conducted an RCT in Post-acute coronary syndrome with left ventricular systolic dysfunction (n=80). Sacubitril/valsartan vs. Ramipril was evaluated on Improvement in left ventricular ejection fraction at 6 months (p=0.275). Sacubitril/valsartan and ramipril demonstrated similar efficacy in improving left ventricular ejection fraction at 6 months in post-acute coronary syndrome patients (p=0.275).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: